Analysts at StockNews.com began coverage on shares of Global Cord Blood (NYSE:CO – Get Free Report) in a research note issued on Monday. The brokerage set a “strong-buy” rating on the medical research company’s stock.
Global Cord Blood Price Performance
Shares of NYSE:CO opened at $2.99 on Monday. The firm’s 50 day simple moving average is $1.23 and its two-hundred day simple moving average is $1.53. The company has a market capitalization of $363.44 million, a P/E ratio of 4.67 and a beta of 0.16. Global Cord Blood has a 1-year low of $2.03 and a 1-year high of $5.50.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Clark Financial Services Group Inc. BD bought a new position in shares of Global Cord Blood during the 1st quarter valued at approximately $37,000. Northern Trust Corp bought a new position in Global Cord Blood during the second quarter valued at $96,000. Natixis Advisors L.P. grew its stake in shares of Global Cord Blood by 5.6% in the 2nd quarter. Natixis Advisors L.P. now owns 199,880 shares of the medical research company’s stock worth $592,000 after buying an additional 10,550 shares in the last quarter. Finally, Moneta Group Investment Advisors LLC increased its holdings in shares of Global Cord Blood by 99,844.5% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 26,093,520 shares of the medical research company’s stock worth $77,957,000 after buying an additional 26,067,412 shares during the last quarter.
Global Cord Blood Company Profile
Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.
- Five stocks we like better than Global Cord Blood
- What Are Dividend Contenders? Investing in Dividend Contenders
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- How to Invest in Cybersecurity
- MarketBeat Week in Review – 11/13 – 11/17
- 3 REITs to Buy and Hold for the Long Term
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Global Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Cord Blood and related companies with MarketBeat.com's FREE daily email newsletter.